Abstract:Abstract Introduction Vitiligo is an acquired depigmenting skin condition characterized by the loss of skin pigmentation, impacting 0.5% to 2% of the global population.1–3 Vitiligo presents as distinct depigmented patches resulting from autoimmune melanocyte destruction. Individuals with visual vitiligo lesions often experience negative body image, diminished self-confidence, discomfort, and overall lower quality of life (QoL).4 While there are medical treatment options available, these can be associated with poor efficacy and low medication compliance.4 Residual lesions after treatment may require surgical intervention which allows for melanocyte transplantation from an area that is pigmented to one that is lacking functional melanocytes. Through a point-of-care device, a non-cultured autologous skin cell suspension (ACSC) can be prepared using a small skin sample; the ASCS contains healthy melanocytes and is immediately applied onto skin treated with ablative laser to aid in the repigmentation of affected areas. Objective The objective of this study was to evaluate the one-time application of ASCS, with a 1:20 donor to treatment site expansion ratio, for the safe and effective repigmentation of stable vitiligo lesions. Methods A randomized, within-subject controlled, central observer-blinded study was conducted to compare the clinical performance of laser ablation, ASCS, and NB-UVB to NB-UVB alone for repigmentation of stable vitiligo lesions in adults. Subjects received NB-UVB phototherapy on both ASCS-treated and controlled lesions as per recommended by the Vitiligo Working Group. Repigmentation of ASCS-treated and control lesions were categorized by a Central Review Committee (CRC) of blinded dermatologists as one of the following: 0%-25%, 26%-50%, 51%-79%, or 80-100%. The primary effectiveness endpoint was defined as the proportion of lesions achieving ≥80% repigmentation for ASCS-treated versus control areas at Week 24. Early regimentation was assessed at Weeks 4 and 12 as a post hoc analysis. Results A significantly higher proportion of the ASCS-treated areas (36.0%, n = 9) compared to control-treated areas (0.0%) attained ≥80% repigmentation at Week 24 (P = 0.012). At Week 4, 30.4% (n = 7/23) of ASCS-treated areas had ≥26% repigmentation compared to 4.3% (n = 1/23) in the control areas. At Week 12, 56.5% (n = 13/23) of ASCS-treated areas had ≥26% repigmentation compared to 21.7% (n = 5/23) in the control areas. At Week 24, 64% (n = 16/25) of ASCS-treated areas had ≥26% repigmentation compared to 28% (n = 7/25) in the control areas. Conclusion A one-time treatment of ASCS, with the addition of NB-UVB, can result in excellent repigmentation results by 24 weeks, with most subjects seeing ≥26% repigmentation as early as 4 to 12 weeks.

Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy

Low‐Dose Baricitinib Plus Narrow‐Band Ultraviolet B for the Treatment of Progressive Non‐Segmental Vitiligo: A Prospective, Controlled, Open‐Label Study

Clinical study on NB-UVB combined with Tuibai Decoction in the treatment of vitiligo

Narrow-band ultraviolet B (NB-UVB) therapy in the treatment of vitiligo

Combination Therapy of Orally Administered Glycyrrhizin and UVB Improved Active-Stage Generalized Vitiligo

Efficacy of Both Autologous Epidermal Grafting and Narrow Band Ultraviolet B Radiation on Stable Vitiligo

Repigmentation by combined narrow‑band ultraviolet B/adipose‑derived stem cell transplantation in the mouse model: Role of Nrf2/HO‑1‑mediated Ca2+ homeostasis

Triple-combination treatment with oral α-lipoic acid, betamethasone injection, and NB-UVB for non-segmental progressive vitiligo.

Efficiency of Tuibai Decoction Combined with NB-UVB Irradiation in Treating Vitiligo

Vitiligo: From Pathogenesis to Treatment

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review

Tofacitinib for the Treatment of Refractory Progressive Vitiligo: A Retrospective Case Series

Impact of Combined Phototherapy and Melanocyte Transplantation on Indicators of Vitiligo Activity

Triple combination treatment with fractional CO2 laser plus topical betamethasone solution and narrowband ultraviolet B for refractory vitiligo: a prospective, randomized half-body, comparative study.

Treatment of Vitiligo with NB-UVB: A Systematic Review

Acceleration of Melanocyte Senescence by the Proinflammatory Cytokines IFNγ and TNFα Impairs the Repigmentation Response of Vitiligo Patients to Narrowband Ultraviolet B (NBUVB) Phototherapy

Randomized clinical trial of combined therapy with oral -lipoic acid and NB-UVB for nonsegmental stable vitiligo

Ablative Fractional Co2 Laser Aided Delivery of Long-Acting Glucocorticoid in the Treatment of Acral Vitiligo: a Multicenter, Prospective, Self-Bilateral Controlled Study

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report

543 - Early repigmentation of stable vitiligo through point-of-care melanocyte transfer using non-cultured autologous skin cell suspension